Development Plans For Leniolisib For Additional Primary Immunodeficiencies
13/12/2023 06:37
Dec 13 (Reuters) - Pharming Group NV PHAR.AS :
* REG-PHARMING GROUP ANNOUNCES DEVELOPMENT PLANS FOR
LENIOLISIB
FOR ADDITIONAL PRIMARY IMMUNODEFICIENCIES (PIDS)
* PHASE 2 CLINICAL TRIAL INITIATION PLANNED FOR 2Q 2024
* ANNOUNCES TODAY EXPANSION OF ITS RARE DISEASE PIPELINE
WITH
PLANS TO DEVELOP LENIOLISIB FOR ADDITIONAL PRIMARY
IMMUNODEFICIENCIES (PIDS) BEYOND ACTIVATED PHOSPHOINOSITIDE
3-KINASE DELTA SYNDROME (APDS)
Source text for Eikon: ID:nGNE7h09HB
Further company coverage: PHAR.AS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))